FRESCO-2
A selective VEGF-receptor pill gave a modest but real survival gain in patients with no remaining standard treatment.
OS 7.4 vs 4.8 months (HR 0.66, Lancet 2023). FDA approval November 2023. Better tolerated than regorafenib; hypertension and hand-foot syndrome are the main toxicities.
- Median 7.4 vs 4.8 months with Fruquintinib compared with Placebo; about 2.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 34 percent lower chance of the event at any given time (hazard ratio 0.66, likely range 0.55 to 0.8).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Refractory metastatic colorectal cancer after all standard therapies: fruquintinib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- TrialSUNLIGHT
Shares Tae Won Kim, VEGF / VEGFR, Colorectal cancer.
- ProductTrifluridine/tipiracil
Shares Tae Won Kim, Colorectal cancer.
- PersonAlan P. Venook
Shares VEGF / VEGFR, Colorectal cancer.
- PersonRui-Hua Xu
Shares Fruquintinib, Colorectal cancer.
- Key paperCodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer
Shares Tae Won Kim, Colorectal cancer.
- InstitutionZhongshan Hospital, Fudan University
Shares VEGF / VEGFR, Colorectal cancer.
- TrialPARADIGM
Shares VEGF / VEGFR, Colorectal cancer.
- Key paperKEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer
Shares Tae Won Kim, Colorectal cancer.